Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
82.48
+2.24 (2.79%)
At close: Jan 29, 2026, 4:00 PM EST
81.01
-1.47 (-1.78%)
After-hours: Jan 29, 2026, 5:18 PM EST

Bright Minds Biosciences Statistics

Total Valuation

DRUG has a market cap or net worth of $790.63 million. The enterprise value is $729.66 million.

Market Cap790.63M
Enterprise Value 729.66M

Important Dates

The next estimated earnings date is Friday, February 13, 2026, after market close.

Earnings Date Feb 13, 2026
Ex-Dividend Date n/a

Share Statistics

DRUG has 7.79 million shares outstanding. The number of shares has increased by 59.58% in one year.

Current Share Class 9.73M
Shares Outstanding 7.79M
Shares Change (YoY) +59.58%
Shares Change (QoQ) +2.11%
Owned by Insiders (%) 16.40%
Owned by Institutions (%) 40.64%
Float 6.07M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 13.42
P/TBV Ratio 13.42
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 36.10, with a Debt / Equity ratio of 0.00.

Current Ratio 36.10
Quick Ratio 35.68
Debt / Equity 0.00
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -379.73

Financial Efficiency

Return on equity (ROE) is -27.93% and return on invested capital (ROIC) is -19.38%.

Return on Equity (ROE) -27.93%
Return on Assets (ROA) -18.80%
Return on Invested Capital (ROIC) -19.38%
Return on Capital Employed (ROCE) -16.59%
Weighted Average Cost of Capital (WACC) 1.34%
Revenue Per Employee n/a
Profits Per Employee -$337,686
Employee Count26
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +172.18% in the last 52 weeks. The beta is -0.53, so DRUG's price volatility has been lower than the market average.

Beta (5Y) -0.53
52-Week Price Change +172.18%
50-Day Moving Average 79.77
200-Day Moving Average 49.97
Relative Strength Index (RSI) 47.84
Average Volume (20 Days) 254,992

Short Selling Information

The latest short interest is 336,924, so 4.33% of the outstanding shares have been sold short.

Short Interest 336,924
Short Previous Month 307,407
Short % of Shares Out 4.33%
Short % of Float 5.55%
Short Ratio (days to cover) 1.87

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -9.77M
Pretax Income -8.78M
Net Income -8.78M
EBITDA n/a
EBIT -9.77M
Earnings Per Share (EPS) -$1.28
Full Income Statement

Balance Sheet

The company has $59.52 million in cash and $90,299 in debt, with a net cash position of $59.43 million or $7.63 per share.

Cash & Cash Equivalents 59.52M
Total Debt 90,299
Net Cash 59.43M
Net Cash Per Share $7.63
Equity (Book Value) 58.90M
Book Value Per Share 7.71
Working Capital 58.85M
Full Balance Sheet

Cash Flow

Operating Cash Flow -6.24M
Capital Expenditures n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

DRUG does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -59.58%
Shareholder Yield -59.58%
Earnings Yield -1.11%
FCF Yield n/a

Analyst Forecast

The average price target for DRUG is $106.75, which is 29.43% higher than the current price. The consensus rating is "Strong Buy".

Price Target $106.75
Price Target Difference 29.43%
Analyst Consensus Strong Buy
Analyst Count 6
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on July 14, 2023. It was a reverse split with a ratio of 1:5.

Last Split Date Jul 14, 2023
Split Type Reverse
Split Ratio 1:5

Scores

Altman Z-Score n/a
Piotroski F-Score 2